Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Acadia faces US federal probe into Nuplazid marketingAcadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into Share XAcadia faces US federal probe into Nuplazid marketinghttps://pharmaphorum.com/news/acadia-faces-us-federal-probe-into-nuplazid-marketing/
Vertex CEO hints at ‘new ideas’ to bring Orkambi to UK patientsVertex CEO Jeffrey Leiden has offered an olive branch to negotiators in the UK that could see the Share XVertex CEO hints at ‘new ideas’ to bring Orkambi to UK patientshttps://pharmaphorum.com/news/vertex-ceo-hints-at-new-ideas-to-bring-orkambi-to-uk-patients/
FDA approves Janssen’s ketamine-based nasal antidepressantThe FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment Share XFDA approves Janssen’s ketamine-based nasal antidepressanthttps://pharmaphorum.com/news/fda-approves-janssens-ketamine-based-nasal-antidepressant/
UK politicians to grill Vertex CEO over CF price drug rowThe CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating Share XUK politicians to grill Vertex CEO over CF price drug rowhttps://pharmaphorum.com/news/uk-politicians-to-grill-vertex-ceo-over-cf-price-drug-row/
Napp launches Neulasta biosimilar in UKNapp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval Share XNapp launches Neulasta biosimilar in UKhttps://pharmaphorum.com/news/napp-launches-neulasta-biosimilar-in-uk/
Bayer completes US filing for prostate cancer drug darolutamideBayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible Share XBayer completes US filing for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-completes-us-filing-for-prostate-cancer-drug-darolutamide/
Pharma CEOs grilled by US Senators over drug pricesPharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription Share XPharma CEOs grilled by US Senators over drug priceshttps://pharmaphorum.com/news/pharma-ceos-grilled-by-us-senators-over-drug-prices/
Catalyst defends huge US price hike for rare disease drugCatalyst Pharmaceuticals has defended hiking the price of the rare disease drug Firdapse (amifampridine) from virtually nothing to Share XCatalyst defends huge US price hike for rare disease drughttps://pharmaphorum.com/news/catalyst-defends-huge-us-price-hike-for-rare-disease-drug/
